PT-141 Palatin.

Current opinion in investigational drugs (London, England : 2000)2004PMID: 15134289

Plain Language Summary

A brief drug development summary describing PT-141 (Palatin Technologies) as a nasal spray for erectile dysfunction and female sexual dysfunction, reporting completion of phase IIb in ED in 2003 and planned phase III start in 2005. Historical document capturing PT-141's early development trajectory.

Abstract

Palatin, under license from Competitive Technology, is developing the peptide PT-141, a synthetically modified analog of PT-14, as a nasal spray for the potential treatment of erectile dysfunction (ED) and female sexual dysfunction. In September 2003, Palatin had completed a phase IIb trial in patients with ED and in February 2004, Palatin planned to start phase III trials in early 2005.

Authors

Hedlund, Petter